#Shanghai #CAR-T therapies #Oricell Therapeutics #GPC3

Oricell Therapeutics Secures $110 Million Funding

Oricell Therapeutics, a prominent name in the biotechnology sector, has successfully closed a pre-IPO financing round that raised over $110 million, a move that is set to significantly boost its efforts in developing cutting-edge CAR-T therapies for solid tumors.

The financing round, co-led by notable firms like Vivo Capital and Beijing Medical and Health Care Industry Investment Fund, also saw participation from other key investors such as Qiming Venture Partners and a global healthcare fund. This influx of capital will enable Oricell to accelerate its global operations and enhance its clinical development capabilities, thereby paving the way for future milestones in the capital market.

As a pioneering company in cell therapy, Oricell is dedicated to developing effective CAR-T therapies that can have a significant impact on global health. The company has already made remarkable progress with its lead asset, Ori-C101, which targets GPC3—a promising candidate for treating advanced hepatocellular carcinoma (HCC). Preliminary data from clinical trials, including investigator-initiated trials and Phase 1 studies, have showcased a best-in-class efficacy and safety profile for Ori-C101. Highlighted at esteemed conferences such as the ASCO Annual Meeting, Ori-C101 is on track to potentially become the first globally approved CAR-T therapy for HCC, which would mark a significant achievement in cancer treatment.

The support from investors underscores Oricell's commitment to innovation and leadership in the oncology space. Dr. Huanfeng Yang, Chairman and CEO of Oricell, expressed his belief that this significant funding is a testament to the global promise of their research and the dedication of their team. With several clinical programs approaching crucial turning points, Oricell aims to expedite the development of its core assets while also exploring revolutionary technologies like in vivo CAR-T capabilities.

Moreover, Oricell is not just focused on enhancing its existing products but is also exploring a diverse portfolio of next-generation modalities. The company is advancing its research into secreted, rapid production, and in vivo CAR-T programs, which could revolutionize how solid tumors are treated in the future.

Comments from stakeholders reflect the confidence in Oricell's growth trajectory, with Mr. Shan Fu from Vivo Capital emphasizing the need for innovative solutions in oncology, particularly for the challenging domain of solid tumors. He advocated for Oricell's pragmatic vision and their